ŀ	<b>f</b> ~
	~

# GUIDELINES FOR THE EMERGENCY MANAGEMENT OF INJURIES (EMI) AND POST-EXPOSURE PROPHYLAXIS (PEP)

BLOODBORNE VIRUS (BBV) EXPOSURE PATIENT MANAGEMENT FORM

Reporting date:	_	FORM CO	MPLETED BY:		
Reporting time:					
	SECTION 1: RE	CIPIENT DETAILS			
Name:	Recipient registered		□ Allergies ( <i>Please list</i> ):		
Date of birth:	GP Name:  GP Address:				
Email address:	GP Telephone	number:	<ul> <li>Recipient is living with HIV</li> <li>Recipient has known HBV infection</li> <li>Recipient has known HBV vaccination</li> <li>Recipient has known HCV infection</li> </ul>		
Phone number:	□ Recipient not registered with GP		□ Treated or self-cleared □ Active		
Sex assigned at birth:  Male Female Unknown Other	Past medical history (incl. immunosuppression)		<ul> <li>Pregnant</li> <li>Breastfeeding</li> </ul>		
Gender identity: □ Male □ Female □ Non-binary □ Unknown □ Other			For sexual exposures only Recipient has a history of previous treated syphilis Please provide details of past syphilis treatment		
	Medications (Please list):				
	RELEVANT VACCI	NATIONS RECEIVED			
HEPATITIS B		TETANUS Date of last vaccination:			
Antibody titre (if known):					
	SECTION 2: DET	AILS OF EXPOSURE			
Date of exposure: Time of exposure: Hours since exposure:		EXPOSURE TYPE <ul> <li>Needlestick / Sharps</li> <li>Human bite</li> <li>Mucous membrane or non-intact skin</li> </ul>	s		

NEEDLESTICK EXPOSURE DETAILS				
NEEDLE DETAILS   Solid needle  Hollow needle Unknown needle type  Other	BLOOD PRESENT ON NEEDLE			
HUMAN BITE				
WOUND DETAILS	BLOOD PRESENT ON SOURCE			
EXPOSURE OF MUCOUS MEN	/BRANE OR <u>NON-INTACT</u> SKIN			
FLUID  Saliva, Tears, Sweat, Urine, Faeces Blood, CSF, Synovial, Pleural, Peritoneal, Pericardial, Amniotic fluid, Semen, Vaginal secretion	RECIPIENT EXPOSURE TYPE         Intact skin         Non-intact skin         Mucous membrane         Unknown			
TYPE (Select all that apply)				
<ul> <li>Receptive anal</li> <li>Insertive anal</li> <li>Receptive oral</li> <li>Insertive oral</li> <li>Receptive vaginal</li> <li>Insertive vaginal</li> </ul>	<ul> <li>Sexual assault</li> <li>OTHER DETAILS</li> <li>Condom used</li> <li>Condom intact</li> <li>Ejaculation</li> </ul>			
SECTION 3: SIGNIFIC	CANCE OF EXPOSURE			
Was the exposure significant?       Yes       No         Please select 'yes' if details in Section 2 meet criteria for a significant exposure, outlined in Chapter 3 of the EMI PEP quidelines.         IF YES: Proceed to Section 4.       IF NO: Discharge patient and reassure. Provide information leaflet 'No Risk of Exposure.'				
SECTION 4: DET	AILS OF SOURCE			
Source identity known	Source is part of a group considered to have a higher prevalence of			
<ul> <li>Source identity inform</li> <li>Source identity unknown</li> <li>SOURCE STATUS (If known)</li> <li>Source is a person living with HIV</li> <li>On ART &gt;6 months with suppressed viral load</li> <li>On ART &lt;6 months or not on (effective) ART</li> <li>HIV status unknown</li> <li>Source diagnosed with HBV</li> <li>Source diagnosed with HCV</li> <li>Source immunocompromised</li> </ul>	BBVs than the general population BBVs than the general population BBVs than the general population Born in a high prevalence country ( <i>See <u>EMI PEP Guidelines</u> Appendix 1</i> ) Source identifies as gay, bisexual or other man who has sex with men (gbMSM) Person who injects drugs (PWID) Prisoner Sex worker Sex worker Sexual partner(s) with BBV Recipient of blood / blood products ( <i>pre August 1973 HBV</i> , <i>pre oct 1985 HIV</i> , <i>pre oct 1991 HCV</i> ) Other ( <i>please specify</i> ):			
SOURCE TESTING   Source consent received for testing  Implications of testing discussed  Consent sought to disclose test results to recipient	REASON FOR NOT TESTING SOURCE         Source identity not known         Source did not consent         Source unable to give consent         Source deceased         Other (please specify)			

		SOL	JRCE TESTING RECORD			
	SOURCE HIV	SOURCE HBV		SOURCE HCV		
Date of last test Date		Date of last t	ate of last test		Date of last test	
HIV Ab/Ag Positive Negative	IF POSITIVE: Viral load: Date of viral load testing: On ART:	HBsAg       IF POSITIVE:         Positive       HBeAg         Negative       HBeAg         Anti-HBe		Anti-HCV Positive Negative	IF POSITIVE:         RNA positive         □ Yes □ No         Viral load         Date of viral load testing:         DAA (if applicable)	
	SECTION 5: MA		F RECIPIENT FOLLOWING SIGNIF	CANT EXPOSUR	E	
☐ App □ Recipient ve □ Advised con	oods taken sting • storage only propriately labelled ' <i>Possible BB</i> ' erbal informed consent received dom use for window period	<i>V exposure – re</i> for testing	ecipient'	ion illness or pos	sitive blood result	
RECIPIENT BAS	ELINE TESTING: See EMI PEP Gu	uidelines <u>Table</u>	5			
	ST CARRIED OUT	D	ATE	RESULTS		
□ HBsAg □ HBsAb*						
□ HBcAb						
□ HCV Ab						
□ HIV 1&2 Ag/	/Ab					
□ STI testing (s	sexual exposure)					
□ Syphilis (sex	ual exposure)					
□ Pregnancy to	est					
□ ALT (if HIV P	EP prescribed)					
prescribed)	nd eGFR (if PEP HIV					
* Unless previo	ous evidence of Anti-HBs > 10 ml	U/ml after com	pleting a full course of hepatitis	B vaccination		

## SECTION 6: FOLLOW-UP AND/OR ONWARD REFERRAL

Onward referral for follow-up should be made in a timely manner as per EMI PEP guidelines and locally agreed protocols.

# Occupational exposure-related follow up at Healthcare Worker (HCW) Recipient's Occupational Health department:

- The HSE Occupational Health Services <u>do not</u> complete the **immediate management** of blood and bodily fluid exposures including the prescribing of HIV or Hepatitis B Post Exposure Prophylaxis.
- HCWs who sustain BBFEs at work should be referred to the HSE Occupational Health Service (OHS), using the recommended **Referral Letter** to HSE Occupational Health Services after the **Immediate Management** has been completed.
  - The Immediate Management includes the following and should be completed within 72 hours of the exposure:
    - The **emergency management** of injuries.
    - The completion of the **source risk assessment** and **source serology sampling**, as per the EMI guidance.
      - **Post-exposure prophylaxis** for Hepatitis B and HIV if clinically indicated.
  - The HSE Occupational Health service upon receipt of a **Completed Referral Letter** will provide the following:
    - Recipient **interval testing** if indicated For Hepatitis B, C and HIV.
    - Recipient Fitness for Duty assessment.
    - Completion of Hepatitis B vaccination course for **the recipient** if applicable.
- The Referral Form is available at the link here.

#### HIV PEP INDICATED (urgent, in 3-5 days — appointment to be arranged as per local pathway)

 $\Box Y \Box N$ 

If yes, reason: \_\_\_\_\_

Details of drug: \_\_\_\_

HBV vaccination	Referred to Sexual Assault Treatment Unit (SATU)
□ HBIG	Social worker contacted
□ Antibiotics	□ Further testing (See EMI PEP guidelines <u>Table 5</u> )
Counselling	□ Referral to Occupational Health (where recipient interval testing,
Tetanus vaccination	Fitness for Duty assessment, Completion of HBV vaccination course may
Emergency contraception (if indicated)	be necessary - form available at the link here.)
	Referral to General Practitioner (form available at the link <u>here.</u> )

#### **SECTION 7: OTHER DETAILS**

### POINTS FOR DISCUSSION WITH RECIPIENT (IF HIV PEP INDICATED)

- 1. The need for baseline bloods (including HIV test)
- 2. Antiretrovirals and efficacy as PEP
- 3. Importance of adherence to optimise efficacy
- 4. Start PEP as soon as possible to maximise efficacy
- 5. Advised too late if commenced after 72 hours (post-exposure)
- 6. Length of PEP is 28 days
- 7. Drug side effects discussed
- 8. Drug interactions discussed (including multivitamins, iron, antacids)
- 9. Advised to seek urgent attention if symptoms of seroconversion
- **10.** PEP leaflet provided

#### ADDITIONAL DETAILS AS REQUIRED BY ASSESSING HEALTHCARE PROFESSIONAL